FDA reviewing heart risks of Glaxo diabetes pill

(AP)—The Food and Drug Administration will hold a meeting in June to reassess the safety of GlaxoSmithKline's former blockbuster diabetes drug Avandia.

Avandia was severely restricted in 2010 due to concerns about its impact on the heart.

Regulators announced the highly unusual move in a government notice Friday. The FDA will ask a panel of outside experts to review a new analysis of the key study about Avandia's heart risks.

A spokeswoman for Glaxo said the drug company commissioned researchers at Duke University to reanalyze the study, and submitted the results to the FDA last year.

The FDA first approved the drug in 1999 and it became the top-selling in the world by 2006. Sales began plummeting in 2007 after researchers began questioning the drug's safety.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Glaxo adds safety restrictions to Avandia label

Feb 07, 2011

(AP) -- GlaxoSmithKline says it has updated the labeling of its diabetes pill Avandia to include safety restrictions ordered by federal health authorities because of the drug's links to heart attack.

Glaxo defends handling of Avandia heart risks

Feb 24, 2010

(AP) -- GlaxoSmithKline said Wednesday a Senate report criticizing its handling of heart risks with its diabetes drug Avandia "mischaracterizes and distorts" the company's record.

FDA issues hold on much-debated Avandia study

Jul 21, 2010

(AP) -- Federal health officials are barring new patients from enrolling in a safety study of GlaxoSmithKline's controversial diabetes pill Avandia, a week after a panel of experts ruled that the drug increases ...

FDA review spotlights heart risk of diabetes pill

Jul 09, 2010

(AP) -- A review by federal health scientists reinforces potential ties between the diabetes pill Avandia and heart attack and death, opening the door for government action, including a possible withdrawal of the once blockbuster ...

US panel backs novel diabetes pill from J&J (Update)

Jan 10, 2013

A panel of U.S. health experts ruled Thursday that an experimental diabetes drug from Johnson & Johnson is safe and effective, though lingering safety questions must be tracked over the long term.

Recommended for you

New system targets germs in donated blood plasma

11 hours ago

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

India court blocks Bayer generic drug appeal

Dec 13, 2014

An Indian court has rejected German drug giant Bayer's bid to block a generic version of its blockbuster cancer treatment Nexavar by a local drugmaker, a move hailed by activists on Saturday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.